RxDoctor Payments Data

Courtney Farris, APRN

Family · Austin, TXNPI 1588148720

Payments from drug & device makers

$1,564in general payments, 2019–2025

Across 22 payments — averaging $71.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$491
  • Scpharmaceuticals Inc.$279
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$219
  • Amgen$195
  • Novo Nordisk$125
  • Bayer$97
  • plus $158 from 3 others

What the payments were for

  • Food & beverage$1,564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,564 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$19,225
Medicare patients
142
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$24,452
XareltoRivaroxaban14$10,879
Prasugrel Hcl12$1,371
Ezetimibe41$771
Rosuvastatin Calcium36$658
Amlodipine Besylate51$427
Metoprolol Succinate38$381
Isosorbide Mononitrate ErIsosorbide Mononitrate32$362
Atorvastatin Calcium47$358
Carvedilol54$348
Lisinopril43$326
Losartan Potassium29$274
Hydralazine Hcl21$194
Potassium Chloride16$194
ClopidogrelClopidogrel Bisulfate18$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$60$10,87914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →